尽管兴趣短浅,但Forte生物科学获得“买入”评级,因为CFO提升了股票所有权。 Despite rising short interest, Forte Biosciences receives "buy" ratings as CFO boosts stock ownership.

福特生物科学公司(Forte Biosciences)是一家生物制药公司,开发自发免疫疾病治疗方法。 1月,短期利息增加近20%,达到342 900股。 Forte Biosciences, a biopharmaceutical company developing treatments for autoimmune diseases, saw short interest increase by nearly 20% in January, reaching 342,900 shares. 尽管如此,TD Cowen和Chardan Capital的分析师还是以64美元的价格目标发布了“买入”评级。 Despite this, analysts at TD Cowen and Chardan Capital issued "buy" ratings with a $64 price target. 该公司的CFO最近将他的股票所有权增加了272.50%。 The company's CFO recently increased his stock ownership by 272.50%. Forte Biosciences 的市值为 2320 万美元。 Forte Biosciences has a market cap of $23.20 million.